The global heart pump device market is anticipated to grow at a CAGR of 21.4% during the forecast period (2023-2030). The primary factor supporting the market growth is the continuously rising investments by key players to develop products, and increasing FDA approval. For instance, in May 2023, Magenta Medical closed $55 million funding to support the development of the miniature heart pump. The company intended to advance its clinical programs in the US for receiving its 1st FDA approval. Further, in June 2023, the company initiated its FDA-approved early feasibility study with the Elevate™ percutaneous left ventricular assist device (pLVAD) for the high-risk percutaneous coronary intervention (HR-PCI) indication. The study began with the treatment of two patients of which one in Mount Sinai Health System and one in St. Francis Hospital and Heart Center, both in New York.
Browse the full report description of “Heart Pump Device Market Size, Share & Trends Analysis Report by Type (Implanted Heart Pump Devices and Extracorporeal Heart Pump Devices), by Product (Ventricular Assist Devices, Total Artificial Hearts (TAHs), and Extracorporeal Membrane Oxygenation (ECMO)), and by End-User (Hospital and Cardiac Centers) Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/heart-pump-device-market
In January 2021, CorWave SA raised a funding of worth $40 million from returning investors and 3 new investors. Through this funding, the company intends to develop an implantable heart pump (Left Ventricular Assist Device (LVAD)) based on the wave membrane pump technology. These new funds enabled CorWave to finalize development of its initial product, expanded manufacturing infrastructure, completed regulatory testing required to conduct human implants, and started its human clinical trials. Further, in June 2023, CorWave raised $64M as it prepares to manufacture its LVAD to fund entry into clinical trials and initial manufacturing of its wave membrane LVAD.
In August 2021, the US FDA granted breakthrough device designation to Abiomed’s Impella ECP expandable percutaneous heart pump. The FDA prioritize Impella ECP’s regulatory review processes including design iterations, clinical study protocols and pre-market approval (PMA) application. Impella ECP is the smallest heart pump in the world and the first to be compatible with small bore access and closure techniques. It measures 9 French (3 millimeters) in diameter upon insertion and removal from the body. While in the heart, it expands to support the heart’s pumping function, providing flow greater than 3.5 L/min.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Technology
o By Application
o By End-Use
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Abbott Laboratories, Berlin Heart GmbH, Boston Scientific Corp., Medtronic plc, Terumo Corp., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Heart Pump Device Market Report Segment
By Type
By Product
• Ventricular Assist Devices
By End-Use
Global Heart Pump Device Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/heart-pump-device-market